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Abstract: 1-Deoxysphingolipids (1-deoxySL) are atypical sphingolipids that are formed by the enzyme
serine palmitoyltransferase (SPT) due to a promiscuous use of L-alanine over its canonical substrate L-
serine. Several mutations in SPT are associated with the hereditary sensory and autonomic neuropathy
type I (HSAN1). The current hypothesis is that these mutations induce a permanent shift in the affinity
from L-serine toward L-alanine which results in a pathologically increased 1-deoxySL formation in HSAN1
patients. Also, wild-type SPT forms 1-deoxySL under certain conditions, and elevated levels were found
in individuals with the metabolic syndrome and diabetes. However, the molecular mechanisms which
control the substrate shift of the wild-type enzyme are not understood. Here, we report a novel SPTLC2-
S384F variant in two unrelated HSAN1 families. Affected patients showed elevated plasma 1-deoxySL
levels and expression of the S384F mutant in HEK293 cells increased 1-deoxySL formation. Previously,
S384 has been reported as one of the two (S384 and Y387) putative phosphorylation sites in SPTLC2.
The phosphorylation of wild-type SPTLC2 was confirmed by isoelectric focusing. The impact of an S384
phosphorylation on SPT activity was tested by creating mutants mimicking either a constitutively phos-
phorylated (S384D, S384E) or non-phosphorylated (S384A, Y387F, Y387F+S384A) protein. The S384D
but not the S384E variant was associated with increased 1-deoxySL formation. The other mutations
had no influence on activity and substrate affinity. In summary, our data show that S384F is a novel
mutation in HSAN1 and that the substrate specificity of wild-type SPT might by dynamically regulated
by a phosphorylation at this position.
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Abstract 1-Deoxysphingolipids (1-deoxySL) are atypical
sphingolipids that are formed by the enzyme serine pal-
mitoyltransferase (SPT) due to a promiscuous use of
L-alanine over its canonical substrate L-serine. Several
mutations in SPT are associated with the hereditary sensory
and autonomic neuropathy type I (HSAN1). The current
hypothesis is that these mutations induce a permanent shift
in the affinity from L-serine toward L-alanine which results
in a pathologically increased 1-deoxySL formation in
HSAN1 patients. Also, wild-type SPT forms 1-deoxySL
under certain conditions, and elevated levels were found in
individuals with the metabolic syndrome and diabetes.
However, the molecular mechanisms which control the
substrate shift of the wild-type enzyme are not understood.
Here, we report a novel SPTLC2–S384F variant in two
unrelated HSAN1 families. Affected patients showed ele-
vated plasma 1-deoxySL levels and expression of the
S384F mutant in HEK293 cells increased 1-deoxySL for-
mation. Previously, S384 has been reported as one of the
two (S384 and Y387) putative phosphorylation sites in
SPTLC2. The phosphorylation of wild-type SPTLC2 was
confirmed by isoelectric focusing. The impact of an S384
phosphorylation on SPT activity was tested by creating
mutants mimicking either a constitutively phosphorylated
(S384D, S384E) or non-phosphorylated (S384A, Y387F,
Y387F?S384A) protein. The S384D but not the S384E
variant was associated with increased 1-deoxySL forma-
tion. The other mutations had no influence on activity and
substrate affinity. In summary, our data show that S384F is
a novel mutation in HSAN1 and that the substrate
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specificity of wild-type SPT might by dynamically regu-
lated by a phosphorylation at this position.
Keywords Serine palmitoyltransferase 
1-Deoxysphingolipids  Sensory neuropathy  HSAN1 
Sphingolipids
Introduction
Hereditary sensory and autonomic neuropathy type I
(HSAN1) is an autosomal dominant ulceromutilating neu-
ropathy with variable motor involvement caused by
mutations in six genes: SPTLC1 (Bejaoui et al. 2001;
Dawkins et al. 2001), SPTLC2 (Rotthier et al. 2010), ATL1
(Guelly et al. 2011), RAB7 (Verhoeven et al. 2003),
DNMT1 (Klein et al. 2011) and ATL3 (Kornak et al. 2014).
SPTLC1 and SPTLC2 encode for two of three subunits
of the enzyme serine palmitoyltransferase (SPT) which
catalyzes the condensation of palmitoyl-CoA with L-ser-
ine—the first and rate-limiting step in ceramide de novo
synthesis (Hanada 2003). SPT is catalytically promiscuous
and can also metabolize L-alanine and glycine under certain
conditions (Supplementary Figure 1). This alternative
activity forms an atypical class of neurotoxic 1-deoxy-
sphingolipids (1-deoxySL) which lack the C1 hydroxyl
group of regular sphingolipids (Zitomer et al. 2009; Penno
et al. 2010). They are not able to form higher substituted
sphingolipids like sphingomyelins or glycosphingolipids
and can also not degrade via the canonical pathway which
requires the formation of S1P as a catabolic intermediate.
The HSAN1 mutations in SPT induce a permanent shift
from L-serine toward L-alanine which results in a patho-
logically increased 1-deoxySL formation (Penno et al.
2010; Rotthier et al. 2010). Elevated 1-deoxySL levels
were found in plasma and lymphoblasts of HSAN1 patients
and in plasma and peripheral nerve tissue of transgenic
mice (Penno et al. 2010; Rotthier et al. 2010; Garofalo
et al. 2011). 1-deoxySL are neurotoxic and impair neurite
formation in cultured neurons (Penno et al. 2010).
Also, wild-type SPT can metabolize L-alanine under cer-
tain conditions. Elevated 1-deoxySL levels were found in
individuals with the metabolic syndrome and type 2 diabetes
and might also be involved in the pathology of diabetic neu-
ropathy (Othman et al. 2014). However, the molecular
mechanismwhich controls the substrate shift of the wild-type
enzyme is not understood. Here, we report a novel HSAN1
mutation in SPTLC2 (S384F) which was identified in two
unrelated families. The mutation is associated with signifi-
cantly elevated plasma 1-deoxySL levels. The same residue
(S384) was reported previously as a putative SPTLC2 phos-
phorylation site (Olsen et al. 2006).We therefore investigated
whether a phosphorylation of S384 has an influence on sub-
strate specificity of SPT and whether this regulation is
impaired in the two newly identified HSAN1 families.
Materials and Methods
Ethical Approval
Ethical approval for this study was obtained from the Joint
Medical and Ethics Committee at the National Hospital for
Neurology and Neurosurgery (NHNN). Written informed
consent was obtained from all patients.
Patients
One hundred and seven patients with HSAN were selected
from our inherited neuropathy database. The database
includes patients seen in the peripheral neuropathy clinics
in the NHNN, as well as patients whose DNA was referred
from other hospitals for diagnostic and research testing.
All patients selected had a clinical diagnosis of HSAN,
presenting with progressive distal sensory loss, with or
without ulceromutilating complications or autonomic dys-
function. Because of the overlap between Charcot-Marie-
Tooth Type 2B (CMT2B) and HSAN1, patients with motor
involvement were included; however, sensory features
were always predominant. Diagnosis was based on clinical
phenotype in addition to neurophysiology. All patients
were negative for mutations in SPTLC1 and most were also
negative for mutations in RAB7, NGFB, FAM134B and
NTRK1. Four hundred and seventy-eight British control
chromosomes were screened for the S384F mutation.
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Patient Assessment
All patients found to have mutations were seen and had
detailed clinical and neurophysiological assessments per-
formed, including assessment of neuropathy severity using
the Charcot-Marie-Tooth Neuropathy Score 2 (CMTNS2)
(Murphy et al. 2011). Nerve conduction studies were per-
formed using standard techniques.
Genetic Sequencing
All 12 exons and flanking introns of SPTLC2 were
amplified using Roche polymerase chain reaction (PCR)
reagents. Sequence reactions were performed using Big
Dye Terminator version 3.1 Cycle Sequencing Kit
(Applied Biosystems) and resolved on an ABI 3730xl
Sequencer. Sequence variants were confirmed by repeat
sequencing. Three commonly used prediction programmes,
PolyPhen2 (http://genetics.bwh.harvard.edu/pph/), SIFT
(http://blocks.fhcrc.org/sift/SIFT.html) and aGVGD (http://
agvgd.iarc.fr/), were used to predict the effect of the
mutations on protein function.
PCR comprised the following steps for all exons except
exons 1 and 5:
(1) 95 C for 15 min, (2) 25 cycles of 95 C for 30 s,
60 C (reduced by 0.4 C per cycle) for 30 s, and 72 C
for 45 s, (3) 13 cycles of 95 C for 30 s, 50 C for 30 s,
and 72 C for 45 s and (4) 72 C for 10 min.
For exon 1:
(1) 95 C for 15 min, (2) 38 cycles of 95 C for 30 s,
58 C (reduced by 0.4 C per cycle) for 30 s, and 72 C
for 45 s and (3) 72 C for 10 min. 10 % DMSO
For exon 5:
(1) 95 C for 15 min, (2) 37 cycles of 95 C for 30 s,
51.3 C (reduced by 0.4 C per cycle) for 30 s, and
72 C for 45 s and (3) 72 C for 10 min.
Cloning
SPTLC2 cDNA was amplified by PCR from a cDNA library
and cloned into a mammalian pcDNA 3.1D/V5-His-TOPO
SPTLC2 exon Forward primer Reverse primer Primer conditions
1 CCTACAGAGCCTGCCTTG CGGTGTGGACTGGCGGAG 58 touchdown
2 GGTATAATTCAGCAAATCTC TTTAACTGCATCTGGAATAG 60–50 touchdown
3 TAATGAAATTGCCCTTATAC AATCATATTGTATCCTCAGC 60–50 touchdown
4 ATAGACTTTGTTCTCTCTGC CTAAATGACATGACAAAGTG 60–50 touchdown
5 TCTGAAAAGGACACAACAC TTTAGCTCACTCTGACTGC 51.3
6 AGCTATTAGTGTTTGTGGC TCATTTATACTTTCAAGTGC 60–50 touchdown
7 TATCTGAGGCATGGTTTC TAGACTAATGTTCCCTTCAG 65–55 touchdown
8 ATAATAATGAAGTGCCAAAC GTATTATGAGCCTAAACCAG 60–50 touchdown
9 TCTAGAACTTAGAAGGAAAGG TGCCTATTAGTAAACCTGAC 60–50 touchdown
10 GATAGAATGGAGATAGAGGAG TAAGGACAAGACCATTTTC 60–50 touchdown
11 TTGAAATCTTTGAGGACAG GCTCACAAGAACATCAAG 60–50 touchdown
12 GCACTAGACATAAGTCCTGC ACAGAAGTGTGGTTCCTG 60–50 touchdown
S384D_fw: 50-TCA CAA AGA GTT TTG GTG CTG ATG GAG GAT ATA TTG GAG GC-30
S384D_RV: 50-GCC TCC AAT ATA TCC TCC ATC AGC ACC AAA ACT CTT TGT GA-30
S384E_FW: 50-TTC ACA AAG AGT TTT GGT GCT GAT GGA GGA TAT ATT GGA GGC AAG-30
S384E_RV: 50-CTT GCC TCC AAT ATA TCC TCC CTC AGC ACC AAA ACT CTT TGT GAA-30
S384F_FW: 50-CAA AGA GTT TTG GTG CTT TCG GAG GAT ATA TTG GAG-30
S384F_RV: 50-GCC TCC AAT ATA TCC TCC GAA AGC ACC AAA ACT CTT-30
S384A_FW: 50-CAC AAA GAG TTT TGG TGC TGC AGG AGG ATA TAT TGG AGG CA-30
S384A_RV: 50-TGC CTC CAA TAT ATC CTC CTG CAG CAC CAA AAC TCT TTG TG-30
S384AY387F_FW: 50-CAA AGA GTT TTG GTG CTG CTG GTG GAT TTA TTG GAG GCA AGA-30
S384AY387F_RV: 50-CCT TCT TGC CTC CAA TAA ATC CAC CAG CAG CAC CAA AAC TCT TTG-30
Y387F_FW: 50-GAG TTT TGG TGC TTC TGG TGG ATT TAT TGG AGG CAA GAA GG-30
Y387F_RV: 50-CCT TCT TGT CTC CAA TAA ATC CAC CAG AAG CAC CAA AAC-30
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expression vector. The SPTLC2 mutations S384D, S384E,
S384A, S384F, S384A?Y387F, Y387F and G382V were
introduced by site-directed mutagenesis (primer sequences
below). All constructs were verified by sequencing.
Stable Expression of Mutant and Wild-type SPTLC2
in HEK293 Cells
HEK293 cells (ATCC) were cultured in DMEM (Sigma-
Aldrich) with 10 % fetal calf serum (FisherScientific
FSA15-043) and penicillin/streptomycin (100 U/ml and
0.1 mg/ml, respectively, Sigma-Aldrich). Stable transfec-
tion was performed using TurboFect (Thermo Scientific),
and cells were kept under selection with 400 lg/ml Ge-
neticin (Gibco, Invitrogen). Expression of the constructs
was confirmed by immune blotting and RT-PCR (Supple-
mental Figure 2 A, B).
2D-PAGE Analysis
Total proteins of CHO or Hek293 cells were extracted either
in the presence or absence of a phosphatase-inhibitor
cocktail (Roche). The aliquot without phosphatase inhibitor
was treated with alkaline phosphatase (FastAP, Thermo
Scientific) for 30 min at 37 C. 1 mg of total protein each
was mixed with DeStreakTM Rehydration Solution (Amer-
sham Biosciences) to a final volume of 100 ll and loaded on
a ImmobilineTM DryStrip (GE Healthcare), together with
0.5 % IPG buffer (Amersham Biosciences) by passive
rehydration over-night. Ampholites covered a pH range
from pH 6–11. Iso-electric focusing was carried out on an
Ettan IPGphor (Amersham Biosciences) according to fol-
lowing conditions: Step 1: 300 V, 200 kVh; step 2: 1,000 V,
300 kVh; step 3: 5,000 V, 4,500 kVh; step 4: 5,000 V,
2,000 kVh; and step 5: hold on 500 V. All steps were per-
formed at 20 C, for 3 h with a maximal current of 50 lA
per strip. Focused proteins were subsequently equilibrated
stepwise in 65 mM DTT and 135 mM iodoacetamide (both
in 1 M Tris, 6 M Urea, 30 % v/v glycerol, 2 % w/v SDS,
0.01 % v/v bromphenolblue) with intermediate washing.
Proteins were separated in the second dimension on a 12 %
SDS-PAGE, followed by Western blotting (PVDF mem-
brane) and immune detection using a polyclonal SPTLC2
antibody (Hornemann et al. 2006).
Cell-Based SPT Activity Assay
A total of 200,000 HEK293 cells stably transfected with
SPTLC2wt and SPTLC2 mutants (S384D, S384E, S384F,
S384A, S384A?Y387F and Y387F) were seeded and cul-
tured as described above. After 3 days, the conditioned
medium was exchanged with L-serine and L-alanine deficient
DMEM (Genaxxon BioScience). After a pre-incubation of
two hours, isotope-labeled (2,3,3) d3 L-serine (1 mM)
together with 5 mM (3C13)-labeled L-alanine (Cambridge
Isotope Laboratories, Inc.) was added to the medium. After
24 h, the cells were washed twice with PBS, harvested and
counted (Z2 Coulter Counter, Beckman Coulter). Cells were
centrifuged (8009g, 5 min at 4 C), and pellets were stored
at -20 C for lipid extraction and analysis. The isotope-
labeled sphingoid bases are referred to as d2-SA/d2-SO
(from d3 L-serine) or C13 doxSA/C13 doxSO (from 3C13
L-alanine).
Kinetic Assay with L-Alanine
A total of 400,000 HEK293 cells stable expressing
SPTLC2wt or SPTLC2–S384D were cultured as described
above. At day two, 0–35 mM isotope-labeled L-alanine
(Sigma) diluted in PBS was added to the cells without
changing the media. Cells were cultured for 48 h, washed
twice in PBS, harvested and counted (Z2 Coulter Counter,
Beckman Coulter). Cells were centrifuged (8009g, 5 min
at 4 C), and pellets were stored at -20 C until lipid
extraction and acid–base extraction.
SPT Activity Assay and Lipid Base Extraction
Total protein was extracted from frozen HEK293 cell
pellets using SPT assay buffer (50 mM HEPES pH 8,
1 mM EDTA, 0.2 % Triton-X). 500 lg total protein was
added to a mix of 160 lM palmitoyl-CoA (Sigma), 30 lM
pyridoxal-50-phosphate (Sigma) and either 64 mM L-serine
or 320 mM L-alanine (Sigma). The mix was incubated for
45 min at 37 C under constant shaking at 800 rpm
(Thermomixer comfort, Eppendorf). The in vitro SPT
reaction was stopped by adding 500 ll lipid extraction
buffer containing 4 vol MetOH-KOH and 1 vol CHCl3
spiked with 200 pmol isotope-labeled d7-sphinganine and
d7-sphingosine (Avanti Polar Lipids) as internal extraction
standards. Lipids were base-extracted and analyzed on a
TSQ Quantum Ultra MS analyzer (Thermo Scientific) as
described earlier (Othman et al. 2012)
Extraction and Analysis of Sphingoid Bases
500 microliters MetOH including 200 pmol internal stan-
dard (d7-sphinganine and d7-sphingosine, Avanti Polar
Lipids) was added to 100 ll of plasma or PBS suspended
cells. Lipid extraction was performed for 1 h at 37 C with
constant agitation at 1,000 rpm (Thermomixer comfort,
Eppendorf). Precipitated protein was removed by centrifu-
gation for 5 min at 16,0009g, and the supernatant was
transferred to a new tube. Lipids were hydrolyzed by adding
HCL (4.8 % v/v, for 16 h at 65 C); after neutralization by
adding KOH (1.5 M final concentration), the free sphingoid
50 Neuromol Med (2015) 17:47–57
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bases were extracted with chloroform (92.6 % v/v) under
basic conditions (0.15 N ammoniac). The sphingoid base
profile was analyzed on a TSQ Quantum Ultra MS analyzer
(Thermo Scientific) as described earlier (Othman et al.
2012).
Statistics
One-way ANOVA was used for statistical analysis. Signifi-
cance was verified after Bonferroni multiple-correction.
p values were stated according to the following definition:
****p\ 0.0001, ***p\ 0.001, **p\ 0.01 and *p\ 0.05.
Statistical analysis was performed using GraphPad Prism5.
Results
A Novel SPTLC2 Mutation S384F Was Found in Two
Families
We identified a novel c.1151 C[T (S384F) SPTLC2 variant
in two unrelated HSAN1 index cases. This variant was not
found in 478 control chromosomes nor annotated in the 1,000
genomes (http://www.1000genomes.org/) or the ESP6500
(http://evs.gs.washington.edu/EVS/) database. Further stud-
ies confirmed segregation of the mutation; the mutation was
found in all affected family members who were tested
(Fig. 1a, b). The S384 residue is conserved in mammals but
replaced by alanine in lower vertebrates (Fig. 1c). Poly-
Phen2 and SIFT both predict that this change would be
damaging.
Clinical Details of S384F Patients
The two S384F families could not be genealogically linked
(Fig. 1a). In comparison with other HSAN1 families, patients
from the two S384F families had a rather late onset of disease
in the fourth or fifth decade. Most patients presented with
reduced sensation in the feet and later development of motor
weakness. Sensory loss occurred in a glove and stocking
distribution; pinprick was affected to a greater extent than
vibration perception, similarly to patients with SPTLC1
mutations (Houlden et al. 2006). Sensory complications
including ulcers and accidental burns occurred in all patients,
and some individuals had amputations. Motor involvement
occurred in all families, though to a variable extent. The
disease showed clinical heterogeneity even within families,
e.g., Pedigree A (Fig. 1), III-8 having only mild distal lower
limb weakness at 65 years, while her sibling III-9 had sig-
nificant proximal and distal upper and lower limb weakness
and required a wheelchair since 65 years. None of the
patients had significant autonomic symptoms.
Neurophysiology
Details of neurophysiology from the S384F patients are
shown in Tables 1 and 2. Overall, nerve conduction studies
demonstrated a sensorimotor axonal neuropathy. Sensory
action potentials were absent in the lower limbs and
reduced or absent in the upper limbs. Motor responses were
absent or reduced in the lower limbs with normal or
reduced amplitudes in the upper limbs. Upper limb motor
conduction velocities were either normal or demonstrated
some slowing, similar to what is seen in families with
SPTLC1 mutations (Houlden et al. 2006).
Plasma 1-DeoxySL Are Elevated in S384F Mutation
Carriers
Plasma sphingolipidswere analyzed in four S384Fpatients and
compared to three HSAN1 patients with a known SPTLC1–
C133Wmutation and two healthy controls. The S384F carriers
showed significantly elevated plasma 1-deoxySL levels. Typ-
ical sphingolipid levels were not altered (Fig. 2).
SPTLC2 Is Phosphorylated In Vivo
A previous phospho-proteomic screen revealed two residues
in SPTLC2 (S384 and Y387) as putative phosphorylation
sites (Olsen et al. 2006). Posttranslational modification of
wild-type SPTLC2 was confirmed by 2D-PAGE (Fig. 3a).
The heterogeneity in the isoelectric focusing (IEF) pattern
was reduced to a single spot upon treatment with alkaline
phosphatase. To investigate the effect of a phosphorylation at
S384, we created a set of positive and negative phosphory-
lation mutants (Supplementary Figure 2). The mutant
SPTLC2 variants were stably expressed in HEK293 cells.
Expression levels for protein and mRNA were similar
(Supplementary Figure 2A and B). Compared to SPTLC2wt,
the positive (S384D) and the negative (S384A) mutants
showed a reduced heterogeneity in the isoelectric point (pI)
on 2D-PAGE (Fig. 3b), suggesting that the SPTLC2 protein
is posttranslational modified at S384.
Modifications at S384 Induce a Shift in Substrate
Affinity of SPT
The activity of the mutants was analyzed in two assays. At
cell-free conditions, we observed a decreased canonical
SPT activity with L-serine and an increased activity with
L-alanine for the HSAN1-associated S384F and phosphor-
ylation-mimicking S384D mutant. This effect was not
observed in the SPTLC2wt or the phosphorylation negative
S384A mutant (Fig. 3c, d). These results were verified in
cell culture by stable isotope labeling. The addition of
isotope-labeled d3-serine and C13-alanine to mutant
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expressing HEK293 cells resulted in the time-dependent
incorporation of the isotope label into de novo formed
sphingoid bases. The incorporation of C13-alanine was
significantly increased in the S384F and S384D expressing
cells but not altered in SPTLC2wt or S384A expressing
cells (Fig. 3e, f). In both assays, the activity with alanine
was higher for the S384F mutant than for S384D. However,
in contrast to the cell-free assay, we did not observe a
reduced incorporation of d3-serine in the S384F and S384D
expressing cells (SPT activities for the other variants are
shown in Supplementary Figure 2C and D). Elevated
concentrations of L-alanine in the cell culture medium
increased 1-deoxySL formation in S384D but not in
SPTLC2wt expressing cells (Fig. 3g).
Discussion
HSAN1-associated mutations in SPT induce the patho-
logical formation of an atypical class of neurotoxic
1-deoxySL. Elevated 1-deoxySL levels are consistently
found in plasma of HSAN1 patients and appear to be a
hallmark for the disease (Murphy et al. 2013; Penno et al.
2010; Rotthier et al. 2010). In plasma of healthy individ-
uals, 1-deoxySL levels are typically low but found to be
significantly elevated in patients with the metabolic syn-
drome and diabetes type 2 (Othman et al. 2012; Bertea
et al. 2010). This indicates that wild-type SPT forms
1-deoxySL under conditions of impaired glucose or lipid
homeostasis. As 1-deoxySL are neurotoxic, they might also
contribute to the pathology of diabetes related sequelae—in
particular the diabetic polyneuropathy (Othman et al.
2014). However, increasing the availability of L-alanine did
not automatically increase 1-deoxySL formation by the wt
SPT (Fig. 3g). This shows that 1-deoxySL are not simply
formed as by-products of the normal SPT reaction indi-
cating that additional factors are required to induce the
substrate shift in the wild-type SPT. Interestingly, an
unbiased systematic approach to characterize the in vivo
phospho-proteome in EGF stimulated Hela cells revealed
Fig. 1 Pedigrees of the SPTLC2–S384F families and electrophero-
gram of affected patients and control (a, b). Square = male;
circle = female; diagonal line = deceased; filled symbol = affected;
m/? = heterozygous for mutation; and arrow = proband. c Protein
alignment of the SPTLC2 orthologous from human (Homo sapiens),
mouse (mus musculus), rat (Rattus norwegicus), cattle (Bos Taurus),
zebrafish (Danio rerio), fly (Drosophila melanogaster), baker’s yeast
(Saccharomyces cerevisiae), Candida albicans and the two sphingo-
lipid producing bacteria Sphingomonas multivorum and Sphingomon-
as paucimobilis
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two phosphorylation sites (S384 and Y387) in SPTLC2
(Olsen et al. 2006). The functional consequence of these
modifications was not investigated by the authors, but
phosphorylation was shown to be independent of the EGF
stimulus and did not follow a kinetic pattern (Olsen et al.
2006). Isoelectric focusing revealed heterogeneity in the
isoelectric point (pI) for the SPTLC2 subunit (Fig. 3a).
This heterogeneity was lost after alkaline phosphatase
treatment which supports the concept that SPTLC2 is
phosphorylated.
In parallel and independently, we identified a serine to
phenylalanine exchange at the very same position (S384F)
in two unrelated HSAN1 families. All S384F carriers were
affected and showed increased plasma 1-deoxySL levels.
The plasma levels of the canonical sphingoid bases (SA,
SO) were not altered. Clinically, the S384F mutation was
associated with a typical although late-onset HSAN1 phe-
notype with sensory, and to a lesser extent motor,
involvement. Comparable to other HSAN1 mutations, there
is a considerable clinical heterogeneity between patients
even within the same family (Houlden et al. 2006; Murphy
et al. 2013). The S384F mutant showed reduced activity
with L-serine and increased activity with L-alanine in the
cell-free activity assay (Fig. 3c). As the S384F mutation is
located at a putative phosphorylation site in SPTLC2, we
hypothesized that a phosphorylation at this position might
also influence the substrate specificity of the enzyme. We
therefore created a set of mutants which mimicked either a
constitutively phosphorylated (S384D) or non-phosphory-
lated (S384A) state. Isoelectric focusing revealed a reduced
heterogeneity in the pI for all S384 mutants strongly
indicating the loss of a phosphorylation site. Both the
S384F also the S384D mutants showed increased activity
with L-alanine and a reduced canonical activity with
L-serine in the cell-free activity assay which was not seen
for the S384A mutant or the wild-type SPTLC2. Indepen-
dently, we also tested the activity of other HSAN1 mutants,
including the most frequently found SPTLC1–C133W
mutant in our cell-free conditions (data not shown). Like
for the S384F variant, we observed a reduced activity with
L-serine for the C133W variant but could not see a sig-
nificant incorporation of alanine under these conditions
(data not shown). This contrasts other reports (Gable et al.
2010) which showed an activity with L-alanine also for the
C133W variant under cell-free conditions. However, this
discrepancy is likely related to differences in the experi-
mental setup as Gable et al. analyzed the activity
in microsomal preparations from yeast cells which were
transfected with the human SPTLC1–C133W along with
the human SPTLC2 and the human small SPT subunit a
(ssSPTa). The same group showed previously that the co-
expression of the small SPT subunits ssSPTa and ssSPTb
resulted in a highly increased SPT activity (Han et al.
2009) which explains why the authors could also detect an
activity with alanine for the SPTLC1–C133W mutant.
Without the co-expression of the ssSPTa and b subunits we
could typically detect an activity with L-alanine for the
SPTLC2 mutants (e.g., S384F, A182P) (Murphy et al.
2013) but not for the SPTLC1 variants (data not shown).
To confirm the results from the cell-free assay, we also
analyzed the mutant expressing cells in a metabolic
labeling assay by adding stable isotope-labeled d3-serine
and C13-alanine to the medium. Like for the cell-free assay,
we observed a significantly increased 1-deoxySL formation
in cells expressing the S384F and S384D mutant but not in
cells expressing the SPTLC2wt or the S384A mutant
Fig. 2 Total sphingolipids (a) and 1-deoxySL (b) in patients and
controls. Total sphingolipids from plasma of two healthy controls,
four SPTLC2 S384F and three SPTLC1–C133W patients were
extracted and analyzed by LC–MS after acid–base hydrolysis. Data
are shown as mean, with error bars representing standard deviations.
Total sphingosine (SO) levels were not different between S384F and
C133W carriers compared to healthy controls (a), whereas 1-deoxySL
(deoxy-SO, deoxy-SA) were significantly elevated in the plasma of
patients with the S384F and the C133 W mutations (b). The total
1-deoxySL levels in the plasma of S384F and C133W carriers
were comparable (**** p\ 0.0001, *** p\ 0.001, ** p\ 0.01,
* p\ 0.05)
54 Neuromol Med (2015) 17:47–57
123
Fig. 3 a Changes in the SPTLC2 phosphorylation pattern after
phosphatase treatment. Total protein extract of CHO cells were
extracted in the presence of phosphatase inhibitors (-P’ase) or
alkaline phosphatase (?P’ase). The extract was subjected to isoelec-
tric focusing in the first dimension and separated on a 12 % SDS-
PAGE in the second dimension. SPTLC2 was detected with a
polyclonal anti-SPTLC2 antibody. Phosphatase treatment resulted a
single spot with a uniform isoelectric point (pI). b Extracts from
HEK293 cells expressing SPTLC2wt, S384A, S384F or S384D were
analyzed by 2D-PAGE. SPTLC2wt and mutants were detected using
an anti V5-tag antibody. Isoelectric focusing showed a reduced
heterogeneity in the pI for the mutants in comparison with wild type.
In vitro SPT activity was analyzed in cell extract of SPTLC2wt,
S384F, S384D or S384A expressing HEK293 cells either in the
presence of L-serine (c) or L-alanine (d). Cells were grown in the
presence of isotope-labeled d3-L-serine (1 mM) and (C13)-labeled L-
alanine (5 mM) for 48 h. De novo formed d2-sphinganine (d2-SA)
and d2-sphingosine (d2-SO) (e) and de novo formed C13 -deoxy-
sphinganine (C13-deoxySA) and C13 -deoxy-sphingosine (C13-
deoxySO) (f) (Note during the SPT reaction, one of the deuteriums
of the d3-L-serine is replaced by an unlabeled hydrogen which results
in the formation of d2 labeled sphinganine). Data are shown as mean
with standard deviations (N = 3, ** p\ 0.01). g 1-deoxySL forma-
tion in response to increasing amounts of L-alanine in the cell
medium. SPTLC2wt and S384F, S384D and S384A expressing cells
were cultured in the presence of isotope-labeled L-alanine (5–30 mM)
for 48 h. The graph shows the total de novo formed 1-deoxySLs as a
sum of isotope-labeled deoxy-SA and deoxy-SO
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(Fig. 3f, g). However, in contrast to the cell-free assay, we
did not see a reduced incorporation of d3-serine for the
mutants. This discrepancy might be explained by func-
tional differences between the two assays. It was shown
earlier that cellular SPT activity is tightly regulated by a
metabolic feedback mechanism to prevent a potentially
harmful overproduction of ceramides by the de novo
pathway (Breslow and Weissman 2010). This regulation is
mediated by a set of small proteins (ORM1 and 2 in yeast
and ORMDL1, 2 and 3 in mammalian cells) which act,
depending on their phosphorylation state, as reversible
inhibitors for SPT (Breslow et al. 2010; Siow and Wat-
tenberg 2012; Han et al. 2009; Han et al. 2010; Harmon
et al. 2013). Like SPT, ORM proteins are integral com-
ponents of the endoplasmic reticulum (ER) and it is
therefore likely that such a metabolic feedback control
requires an intact ER structure which is not given for the
cell-free assay conditions. Therefore, the cell-free assay
reflects the maximal SPT activity under saturating substrate
conditions (vmax), whereas the metabolic labeling assay
measures physiological SPT activity in the cellular context.
Interestingly, an increased activity with alanine was only
seen for the S384F and S384D but not for the homologous
S384A or S384E mutant (Supplementary Figure 2D). This
showed that the switch between serine and alanine needs a
specific structural modification in SPTLC2 and is not
simply associated with an arbitrary amino acid exchange at
position 384. The X-ray structure for the mammalian SPT
is not available yet but the molecular structure of the
prokaryotic form is solved for the two sphingolipid gen-
erating bacteria Sphingomonas paucimobilis and Sphingo-
bacterium multivorum (Yard et al. 2007; Ikushiro et al.
2009). In contrast to the mammalian SPT, the prokaryotic
SPT is a homodimer and either soluble (S. paucimobilis) or
loosely attached to the inner cell membrane (S. multivo-
rum) (Ikushiro et al. 2007). The PLP-binding motif is
organized as a coil surrounded by two beta sheets (Sup-
plementary Figure 3A). Modeling the mammalian residues
S384 and Y387 into this structure indicates that Ser384 is
positioned directly in the core of the PLP-binding motif,
pointing outside toward the PLP-binding pocket, whereas
Y387 is rather localized on the beta sheet pointing away
from the binding pocket (Supplementary Figure 3B). This
indicates that S384 rather than Y387 would be accessible
for a kinase from outside. The observation that a specific
phosphorylation of SPT acts as a molecular switch to shift
the substrate specificity of the enzyme from serine to ala-
nine supports a physiological role for the 1-deoxySLs in
the cellular lipid metabolism.
In summary, we showed that S384F is a novel mutation
in HSAN1 and that the substrate specificity of the wild-
type SPT might be dynamically regulated by a phosphor-
ylation at this position. However, the physiological
consequences, underlying regulatory mechanisms and
associated signaling pathways need to be investigated in
further studies.
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